Blood tests predict dementia progression
- Trial ID
- NCT06529744
- Official Title
- Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
- Goal
- Blood tests predict dementia progression
- Status
- RECRUITING
- Sponsor
- University Health Network, Toronto
- Study Type
- OBSERVATIONAL
- Enrollment
- 500 participants
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia, Frontotemporal Dementia, Mild Cognitive Impairment, Corticobasal Syndrome, Progressive Supranuclear Palsy, Parkinson Disease, Primary Progressive Aphasia
Summary For Families
The goal is to improve how confidently clinicians can predict the course of Parkinson's and other neurodegenerative diseases that cause cognitive decline, so patients and families get clearer forecasts about progression and care needs. The approach is observational, gathering peripheral biomarkers like blood tests and other non-brain samples plus detailed clinical and cognitive assessments, then using integrative computational models to combine those signals and produce more accurate, individualized prognoses; it does not change your medical treatment. Adults 30 to 95 with possible or probable mild cognitive impairment or early dementia, who can consent, complete most study procedures, and have a study partner who sees them weekly are being sought.
Locations
- Baycrest, North York, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to improve how confidently clinicians can predict the course of Parkinson's and other neurodegenerative diseases that cause cognitive decline, so patients and families get clearer forecasts about progression and care needs. The approach is observational, gathering peripheral biomarkers like blood tests and other non-brain samples plus detailed clinical and cognitive assessments, then using integrative computational models to combine those signals and produce more accurate, individualized prognoses; it does not change your medical treatment. Adults 30 to 95 with possible or probable mild cognitive impairment or early dementia, who can consent, complete most study procedures, and have a study partner who sees them weekly are being sought.
- Who can participate?
- Participants must be between 30 Years and 95 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.